Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BULLFROG AI Aktie jetzt für 0€ handeln | |||||
22.07. | BullFrog AI Holdings, Inc.: Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development | 4 | GlobeNewswire (USA) | ||
18.07. | RedChip Companies, Inc.: Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 302 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small... ► Artikel lesen | |
20.06. | BullFrog AI Holdings, Inc.: BullFrog AI's Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar | 3 | GlobeNewswire (USA) | ||
12.06. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.06. | BullFrog AI Holdings, Inc.: BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks to Global Biopharma Clients | 2 | GlobeNewswire (USA) | ||
13.05. | BullFrog AI Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
28.04. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.04. | RedChip Companies, Inc.: Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 347 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited (Nasdaq:CNTB) and on... ► Artikel lesen | |
14.03. | BullFrog AI Holdings, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
19.02. | Bullfrog AI Holdings, Inc. (BFRG) to Discuss Breakthrough Psychiatric Research in Fireside Chat on March 5 | 5 | Insider Monkey | ||
27.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Issues Letter to Stockholders | 234 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen | |
17.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Announces Appointment of Chief Financial Officer | 241 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BB BIOTECH | 33,500 | -0,89 % | Aktien KW 30 - Weg erst durch EU-US-Zolleinigung frei? Warten bis zum 1. August? Oder TACO? Bis dahin Einzelwerte im Fokus. News. Evotec. Almonty. Heidelberger Druck. ThyssenKrupp nucera. HELLA. Palfinger. BB Biotech. Sartorius. Berentzen. GFT. STEYR Moto | Aktien: Diese Woche Einzelwerte mit Zahlen im Fokus - Berichtssaison lässt grüssen. Puma bricht ein, Evotec nach unten durchgereicht. Aber auch das: Deutsche Bank zweistelliger Kurssprung. Und so setzte... ► Artikel lesen | |
QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
NOVAVAX | 7,220 | +0,36 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
STRYKER | 324,80 | +0,12 % | Sell Alert: Ronda E Stryker Cashes Out $75.29M In Stryker Stock | ||
ILLUMINA | 81,02 | -0,28 % | Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit | ||
CRISPR THERAPEUTICS | 46,800 | -1,27 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
AAP IMPLANTATE | 1,770 | +2,91 % | aap Implantate: Vollständige Zulassung sämtlicher bislang nicht zugelassener Aktien | Bad Marienberg (www.anleihencheck.de) - Die aap Implantate AG (die "Gesellschaft") gibt bekannt, dass sämtliche bislang nicht zugelassenen Aktien der Gesellschaft (bisherige ISIN DE000A32VP65 und DE000A4096G8)... ► Artikel lesen | |
OCUGEN | 0,860 | +0,42 % | Ocugen sichert sich 20 Millionen US-Dollar über registrierte Direktplatzierung | ||
SANGAMO THERAPEUTICS | 0,389 | -0,28 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 9,236 | -0,39 % | Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus | ||
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -2,96 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
EDITAS MEDICINE | 1,910 | +0,84 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,228 | +1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
TEMPUS AI | 52,00 | -0,95 % | Tempus AI: 90 Prozent Wachstum - KI-Aktie hebt ab | Das US-Unternehmen Tempus AI hat am Freitagmittag die Zahlen für das abgelaufene zweite Quartal vorgelegt. Sowohl bei Umsatz als auch Ergebnis je Aktie konnte der KI-Spezialist besser ab als vom Markt... ► Artikel lesen |